Martin Dreyling Selected Research

Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)

10/2022	Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
5/2022	Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up.
1/2022	Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma.
1/2022	Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
12/2021	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma.
10/2021	Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches.
10/2021	LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome.
9/2021	Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
6/2021	Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches.
5/2021	CAR T-Cells for CNS Lymphoma: Driving into New Terrain?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin Dreyling Research Topics

Disease

83	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 10/2022 - 01/2003
59	Lymphoma (Lymphomas) 07/2022 - 01/2003
39	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022 - 01/2003
29	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 01/2003
27	Neoplasms (Cancer) 05/2021 - 01/2005
20	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 04/2006
18	Disease Progression 01/2022 - 06/2003
13	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 07/2022 - 04/2006
13	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 09/2004
11	Genetic Translocation (Chromosomal Translocation) 01/2017 - 01/2009
5	Infections 01/2021 - 02/2009
4	Neutropenia 12/2021 - 03/2014
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 07/2003
4	Residual Neoplasm 01/2018 - 03/2006
3	Hyperglycemia 11/2021 - 01/2019
3	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2021 - 09/2010
3	Diarrhea 01/2019 - 03/2014
3	Hodgkin Disease (Hodgkin's Disease) 01/2016 - 04/2006
2	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022 - 09/2010
2	Cytokine Release Syndrome 12/2021 - 06/2015
2	Inflammation (Inflammations) 12/2021 - 10/2018
2	Nausea 11/2021 - 07/2014
2	Hypertension (High Blood Pressure) 11/2021 - 01/2019
2	Hemorrhage 01/2019 - 08/2015
2	Pneumonia (Pneumonitis) 01/2019 - 03/2014
2	Multiple Myeloma 01/2016 - 02/2010
2	Chromosome Aberrations (Chromosome Abnormalities) 03/2012 - 02/2009
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 07/2011 - 12/2007
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 09/2010 - 03/2010
1	Orbital lymphoma 07/2022

Drug/Important Bio-Agent (IBA)

47	Rituximab (Mabthera)FDA Link 01/2022 - 01/2003
18	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2003
18	Bendamustine Hydrochloride FDA Link 01/2022 - 07/2007
14	ibrutinibIBA 10/2022 - 08/2013
14	Vincristine (Oncovin)FDA LinkGeneric 01/2022 - 12/2004
14	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 12/2004
14	Cyclin D1IBA 01/2017 - 10/2008
12	Monoclonal AntibodiesIBA 01/2021 - 11/2004
11	Prednisone (Sone)FDA LinkGeneric 01/2022 - 12/2004
10	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 05/2009
9	Proteins (Proteins, Gene)FDA Link 10/2021 - 11/2006
9	Biological ProductsIBA 10/2019 - 04/2006
8	Agammaglobulinaemia Tyrosine KinaseIBA 10/2022 - 08/2013
8	Biomarkers (Surrogate Marker)IBA 12/2021 - 08/2007
8	fludarabineIBA 01/2021 - 01/2003
8	Bortezomib (Velcade)FDA Link 07/2015 - 06/2003
7	Lenalidomide (CC 5013)FDA Link 01/2021 - 09/2008
7	temsirolimus FDA Link 06/2020 - 06/2013
6	AntibodiesIBA 07/2021 - 06/2003
5	Chimeric Antigen ReceptorsIBA 07/2022 - 11/2019
5	copanlisibIBA 11/2021 - 12/2017
5	AntigensIBA 05/2021 - 01/2007
5	Pharmaceutical PreparationsIBA 01/2021 - 02/2007
5	Mitoxantrone (Novantrone)FDA LinkGeneric 07/2007 - 01/2003
4	tisagenlecleucelIBA 07/2022 - 12/2021
4	DNA (Deoxyribonucleic Acid)IBA 09/2015 - 09/2009
4	Proteasome InhibitorsIBA 06/2012 - 09/2008
3	axicabtagene ciloleucelIBA 07/2022 - 01/2021
3	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 08/2016
3	CytokinesIBA 12/2021 - 10/2018
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 11/2021 - 12/2017
3	Interferon-alpha (Interferon Alfa)IBA 09/2021 - 11/2004
3	purineIBA 01/2021 - 09/2004
3	tafasitamabIBA 01/2021 - 01/2020
3	obinutuzumabIBA 08/2019 - 02/2015
3	idelalisibIBA 04/2016 - 03/2014
3	Alkylating AgentsIBA 01/2015 - 02/2010
2	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 08/2016
2	TOR Serine-Threonine KinasesIBA 11/2021 - 09/2008
2	AutoantigensIBA 10/2021 - 10/2008
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 07/2021 - 01/2021
2	Complement System Proteins (Complement)IBA 07/2021 - 01/2005
2	Etoposide (VP 16)FDA LinkGeneric 04/2021 - 01/2021
2	Prednisolone (Predate)FDA LinkGeneric 04/2021 - 06/2014
2	LigandsIBA 10/2019 - 01/2015
2	Protein Isoforms (Isoforms)IBA 01/2019 - 12/2017
2	B-Cell Antigen Receptors (B Cell Antigen Receptors)IBA 10/2017 - 01/2016
2	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2014 - 03/2009
2	enzastaurinIBA 07/2014 - 02/2010
2	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 05/2014 - 11/2009
2	Chlorambucil (Leukeran)FDA Link 03/2011 - 09/2006
2	Alemtuzumab (Campath)FDA Link 03/2010 - 01/2005
2	Radioisotopes (Radionuclides)IBA 01/2009 - 01/2005
2	ProteomeIBA 12/2007 - 11/2006
2	ibritumomab tiuxetan (Zevalin)FDA Link 08/2006 - 01/2005
1	Gemcitabine FDA Link 01/2022

Therapy/Procedure

64	Therapeutics 10/2022 - 06/2003
36	Drug Therapy (Chemotherapy) 10/2022 - 01/2003
19	Stem Cell Transplantation 09/2021 - 11/2004
8	Salvage Therapy 01/2020 - 04/2006
6	Radiotherapy 07/2022 - 05/2013
5	Transplantation 01/2021 - 07/2005
5	Chemoradiotherapy 08/2016 - 11/2004
4	Radioimmunotherapy 12/2011 - 07/2005
3	Cell Transplantation 12/2021 - 05/2019
2	Induction Chemotherapy 01/2022 - 01/2019
2	Time-to-Treatment 01/2018 - 03/2005
2	Precision Medicine 08/2015 - 06/2015
2	Homologous Transplantation 03/2015 - 07/2005
2	Immunotherapy 10/2008 - 07/2007